Latest Development Programs News

Pearl Gull Iron has completed the sale of its Cockatoo Island Project, receiving $4.5 million in cash, a 4% indirect stake in Crestlink Pty Ltd, and ongoing royalties. The transaction positions the company to pursue new growth opportunities while maintaining exposure to the project’s future upside.

Aurum Resources reports multiple high-grade gold intercepts at its 2.41Moz Boundiali Gold Project in Côte d’Ivoire, expanding resource confidence and scale. The company boosts drilling capacity to 12 rigs, targeting major resource updates and a Pre-Feasibility Study in early 2026.

Amaero Ltd has secured a A$4.6 million order from Titomic under their exclusive five-year agreement, marking a significant step in supplying critical refractory and titanium powders for defense applications.

Avecho Biotechnology is close to completing recruitment for the interim analysis cohort of its pivotal Phase III trial testing a CBD capsule for insomnia, with results expected in the first half of 2026.

Encounter Resources reports significant extensions of shallow, high-grade niobium mineralisation east of its Green Mineral Resource Estimate at the Aileron Project, with promising drill results and a major development program planned for 2026.

Locksley Resources has launched an Expression of Interest process to select a leading U.S. engineering firm for the Desert Antimony Mine pilot plant design, marking a critical step toward establishing a domestic antimony supply chain aligned with federal priorities.

Torque Metals has raised $15 million in a placement led by top-tier global investors, setting the stage for an aggressive drilling campaign at its Paris Gold Project in Western Australia.

Imugene Limited has received positive feedback from the FDA, aligning key requirements to progress its azer-cel therapy into a pivotal clinical trial, underscoring its growing promise in blood cancer treatment.

CLINUVEL Pharmaceuticals is significantly expanding its VALLAURIX RD&I Centre in Singapore with a five-year strategic investment, aiming to become a global leader in advanced peptide drug delivery.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

Island Pharmaceuticals has submitted critical responses to the FDA, advancing the development of its antiviral Galidesivir under the Animal Rule pathway. The company awaits FDA feedback expected by early January 2026, setting the stage for upcoming Marburg virus studies.

Argenica Therapeutics has demonstrated that its lead drug candidate ARG-007 does not interfere with the clot-busting agent tenecteplase, fulfilling a critical FDA requirement and advancing its stroke therapy development.